Last reviewed · How we verify
MR4 — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
MR4 (MR4) — Astellas Pharma Inc. MR4 is an investigational compound in development by Astellas Pharma, but its specific mechanism of action is not publicly disclosed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MR4 TARGET | MR4 | Astellas Pharma Inc | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). MR4 — Competitive Intelligence Brief. https://druglandscape.com/ci/mr4. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab